Pharmacogenomic Testing for Warfarin Response — NCD 333 | CMS Coverage Update

TL;DR: The Centers for Medicare & Medicaid Services modified NCD 333 governing pharmacogenomic testing for warfarin response, with an effective date of January 9, 2026. Here's what changes for billing teams.

CMS pharmacogenomic testing coverage policy under NCD 333 in the Medicare system covers CYP2C9 and VKORC1 allele testing only under strict Coverage with Evidence Development (CED) conditions. This policy does not list specific CPT or HCPCS codes in the current version — but the coverage criteria are narrow enough that your billing team needs to understand every condition before submitting a claim. If you bill pharmacogenomic testing for warfarin dosing to Medicare, this update affects your documentation requirements, your eligibility screening, and your exposure to claim denial.

---

Quick-Reference Table

Field	Detail Copy
Payer	CMS (Centers for Medicare & Medicaid Services)
Policy	Pharmacogenomic Testing for Warfarin Response
Policy Code	NCD 333
Change Type	Modified
Effective Date	January 9, 2026
Impact Level	High
Specialties Affected	Clinical laboratory, hematology, cardiology, anticoagulation clinics, internal medicine
Key Action	Confirm every Medicare patient receiving CYP2C9 or VKORC1 testing meets all three CED enrollment criteria before the test is ordered

---

CMS Pharmacogenomic Testing for Warfarin Coverage Criteria and Medical Necessity Requirements 2026

CMS warfarin pharmacogenomic testing coverage policy is not a broad coverage benefit. It is a Coverage with Evidence Development (CED) designation, which means CMS covers this test only when it's provided inside a qualifying clinical study. That distinction matters enormously for medical necessity documentation.

The Centers for Medicare & Medicaid Services first established this coverage on August 3, 2009, under §1862(a)(1)(E) of the Social Security Act. The January 9, 2026 modification preserves the CED framework. Coverage only applies to Medicare beneficiaries who meet all three of the following conditions simultaneously.

Condition one: The patient has not been previously tested for CYP2C9 or VKORC1 alleles. This is a once-in-a-lifetime test by design. If a patient has prior genetic testing on record for these alleles — anywhere, at any time — the test is not covered. Check prior testing history before ordering.

Condition two: The patient has received fewer than five days of warfarin in the anticoagulation regimen for which the testing is ordered. The test is designed to inform starting dose, not to course-correct an established regimen. If a patient is already six days into warfarin therapy when the test is ordered, medical necessity fails.

Condition three: The patient is enrolled in a prospective, randomized, controlled clinical study that meets CMS's specific study standards. This is not a general research exception. The qualifying study must address defined outcome questions comparing pharmacogenomic-guided warfarin management against standard management. Acceptable outcomes under the study include major hemorrhage, minor hemorrhage, thromboembolism related to the primary anticoagulation indication, other thromboembolic events, and mortality.

All three conditions must be met. Miss any one and you have a non-covered service. Document each condition explicitly in the medical record before billing.

The policy also distinguishes the role of this test. CYP2C9 and VKORC1 testing is used to predict warfarin response and approximate a starting dose. It does not replace PT/INR monitoring. Your documentation should reflect that ongoing PT/INR testing continues alongside — not instead of — any pharmacogenomic results.

Prior authorization requirements are not explicitly outlined in NCD 333 as a standalone step, but CED enrollment itself functions as a de facto precondition. If the patient isn't enrolled in a qualifying study, no amount of prior authorization documentation will make this claim payable. Confirm study enrollment first.

Reimbursement for this test flows only through the CED pathway. There is no alternative coverage route in NCD 333 for pharmacogenomic warfarin testing outside a qualifying study.

---

CMS Pharmacogenomic Testing for Warfarin Exclusions and Non-Covered Indications

CMS does not cover CYP2C9 or VKORC1 testing outside the CED framework. That's the central exclusion, and it covers a wide range of scenarios your team will encounter regularly.

Testing ordered for a patient already on an established warfarin regimen — beyond the five-day threshold — is not covered. Testing for a patient who has previously had CYP2C9 or VKORC1 allele testing is not covered. Testing outside an approved clinical study is not covered, regardless of medical need or physician documentation.

The policy does not cover pharmacogenomic testing as a general warfarin management tool. CMS made a deliberate choice here: the evidence base as of the original 2009 NCD, and sustained through this 2026 modification, does not support routine coverage. The real issue for billing teams is that this testing is widely ordered in clinical practice — which means your exposure to claim denial is real if your team hasn't built the right eligibility screens into your workflow.

Genetic counseling or interpretation services associated with this testing are not addressed separately in NCD 333. If your practice bills those services, check for applicable local coverage determinations from your Medicare Administrative Contractor (MAC), as MAC-level policy may address adjacent services.

---

Coverage Indications at a Glance

---

CMS Pharmacogenomic Testing for Warfarin Billing Guidelines and Action Items 2026

This policy is already in effect as of January 9, 2026. If you're billing pharmacogenomic warfarin testing to Medicare now, these steps apply immediately.

Copy Action Items

---

CPT, HCPCS, and ICD-10 Codes for Pharmacogenomic Warfarin Testing Under NCD 333

Covered CPT Codes (When CED Selection Criteria Are Met)

NCD 333 does not list specific CPT or HCPCS codes. The policy defines coverage by condition and study enrollment, not by code enumeration.

Your laboratory billing team should identify the appropriate codes for CYP2C9 and VKORC1 allele testing from your current charge master and cross-reference them against your MAC's local coverage determinations. Do not bill a code to Medicare under NCD 333 without confirming that your MAC recognizes it as applicable to this NCD.

Not Covered / Experimental Codes

No specific codes are listed for non-covered designations in NCD 333. Coverage denials are determined by failure to meet CED criteria, not by code-level exclusion.

Key ICD-10-CM Diagnosis Codes

NCD 333 does not enumerate ICD-10-CM diagnosis codes. The clinical context — anticoagulation therapy with warfarin, candidate status, and the primary indication for anticoagulation — should be captured in your diagnosis coding. Work with your compliance officer to confirm appropriate ICD-10-CM codes for the underlying indication (atrial fibrillation, DVT, pulmonary embolism, mechanical heart valve, etc.) that triggered the warfarin therapy.

---